Reducing immune responses to antibody drug conjugates
Official title: Mitigating ADA Through Site-specific Conjugation Technology
Funded at State University of Ny,binghamton · NIH-10750703 · Data updated 2026-11-12
This study is looking at a new way to make antibody drug treatments safer and more effective by changing how the drug is connected to the antibody, which could help prevent allergic reactions and improve how well the treatment works for patients.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of Ny,binghamton NIH-funded |
| Lab location | 1 site (Binghamton, United States) |
| Project start | December 8, 2022 |
| Funding year | 2023 |
| Award (this year) | $2,500 |
| NIH project number | 3F31GM148053-01S1 |
| Project ID | NIH-10750703 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients who are receiving or are candidates for antibody drug conjugate therapies.
✕Less likely to help
Patients who are not undergoing treatment with antibody drug conjugates or who have contraindications to such therapies may not benefit from this research.
What this research studies
This research investigates a new technology for antibody drug conjugates (ADCs) that aims to reduce the immune response that can occur when patients receive these treatments. The approach focuses on modifying how the drug is attached to the antibody to minimize the development of anti-drug antibodies (ADAs), which can neutralize the drug's effectiveness and cause allergic reactions. By using advanced techniques like NMR and fluorescence, the researchers will explore how to keep the drug hidden from the immune system while still allowing it to work effectively. This could lead to safer and more effective treatments for patients receiving ADC therapies.
Why it matters
Potential benefit: If successful, this research could lead to improved safety and efficacy of antibody drug conjugates, enhancing treatment outcomes for patients.
How similar studies have gone: Other research has shown promise in similar approaches to mitigate immune responses in drug therapies, indicating potential for success in this area.
Where this research is happening
-
State University of Ny,binghamton
Binghamton, United States Active
Researchers
- Principal investigator: Benjamin, Samantha Rene — State University of Ny,binghamton
- Study coordinator: Benjamin, Samantha Rene
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.